Literature DB >> 8603675

Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.

N Baldini1, K Scotlandi, M Serra, T Shikita, N Zini, A Ognibene, S Santi, R Ferracini, N M Maraldi.   

Abstract

The MDR1 gene product P-glycoprotein is a plasma membrane efflux pump which is responsible for multiple drug resistance of cancer cells. Although the ability of multidrug-resistant cells to exclude drugs from the nucleus is a distinctive and possibly the main mechanism for resistance against a number of drugs, including doxorubicin, this phenomenon is not entirely understood. In this paper, the relationship between doxorubicin subcellular distribution and P-glycoprotein activity at different cell sites has been investigated by different techniques. Cytofluorometry and confocal microscopy were used to study doxorubicin subcellular distribution in U-2 OS human osteosarcoma cells and in the multidrug-resistant variant U-2 OS/DX580. Stable levels of doxorubicin accumulation were found in the nuclei of sensitive cells, whereas the absence of detectable levels of drug in the nuclei of resistant cells could be attributed to an energy-dependent mechanism. Moreover, in resistant cells, inhibition of P-glycoprotein activity was able to induce drug accumulation in the nuclei of resistant cells and to achieve cytotoxic effects comparable to those observed in sensitive cells. Similar results were also found in isolated nuclei from U-2 OS/DX580 cells. The expression of P-glycoprotein in U-2 OS/DX580 and in two other multidrug-resistant cell lines (SW948-R-300 and LoVo-R-100) was investigated by confocal microscopy and immunoelectron microscopy, by using a panel of monoclonal antibodies directed against this protein. Higher levels of P-glycoprotein expression, not only in the plasma membrane and inside the cytoplasm, but also in the nucleus, were found in U-2 OS/DX580 and in LoVo-R-100 multidrug-resistant cells compared to their corresponding sensitive cells. SW948-R-300 cells, featuring increased amounts of MDR1 mRNA but lacking P-glycoprotein expression at the cell surface, showed a higher P-glycoprotein immunolabeling only in the nucleus and in the cytoplasm. The localization of P-glycoprotein in the nucleus of multidrug-resistant cells was confirmed also by studies on isolated nuclei and nuclear matrices, and by Western blot analysis on total cell and isolated nuclear extracts. These findings, suggesting the possible involvement of nuclear P-glycoprotein in the regulation of subcellular doxorubicin distribution in multidrug-resistant cells, open new insights on the mechanisms of P-glycoprotein-mediated resistance to anticancer drugs.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8603675

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  16 in total

1.  Breast cancer resistance protein (BCRP/ABCG2) localises to the nucleus in glioblastoma multiforme cells.

Authors:  Prateek Bhatia; Michel Bernier; Mitesh Sanghvi; Ruin Moaddel; Roland Schwarting; Anuradha Ramamoorthy; Irving W Wainer
Journal:  Xenobiotica       Date:  2012-03-08       Impact factor: 1.908

2.  Intracellular distribution of anthracyclines in drug resistant cells.

Authors:  G Arancia; A Calcabrini; S Meschini; A Molinari
Journal:  Cytotechnology       Date:  1998-09       Impact factor: 2.058

3.  Cellular pharmacokinetic mechanisms of adriamycin resistance and its modulation by 20(S)-ginsenoside Rh2 in MCF-7/Adr cells.

Authors:  Jingwei Zhang; Fang Zhou; Xiaolan Wu; Xiaoxuan Zhang; Yuancheng Chen; Beth S Zha; Fang Niu; Meng Lu; Gang Hao; Yuan Sun; Jianguo Sun; Ying Peng; Guangji Wang
Journal:  Br J Pharmacol       Date:  2012-01       Impact factor: 8.739

4.  Kinetics of doxorubicin handling in the LLC-PK1 kidney epithelial cell line is mediated by both vesicle formation and P-glycoprotein drug transport.

Authors:  E Crivellato; L Candussio; A M Rosati; G Decorti; F B Klugmann; F Mallardi
Journal:  Histochem J       Date:  1999-10

5.  Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.

Authors:  Olga V Leontieva; Maria N Preobrazhenskaya; Ralph J Bernacki
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

6.  Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: the role of nuclear hormone response elements.

Authors:  Andrew Owen; Chris Goldring; Paul Morgan; B Kevin Park; Munir Pirmohamed
Journal:  Br J Clin Pharmacol       Date:  2006-08       Impact factor: 4.335

7.  Development of idarubicin and doxorubicin solid lipid nanoparticles to overcome Pgp-mediated multiple drug resistance in leukemia.

Authors:  Ping Ma; Xiaowei Dong; Courtney L Swadley; Anshul Gupte; Markos Leggas; Harry C Ledebur; Russell J Mumper
Journal:  J Biomed Nanotechnol       Date:  2009-04       Impact factor: 4.099

8.  P-glycoprotein is more efficient at limiting uptake than inducing efflux of colchicine and vinblastine in HL-60 cells.

Authors:  X Declèves; O Chappey; B Boval; E Niel; J M Scherrmann
Journal:  Pharm Res       Date:  1998-05       Impact factor: 4.200

9.  P-glycoprotein mediates drug resistance via a novel mechanism involving lysosomal sequestration.

Authors:  Tetsuo Yamagishi; Sumit Sahni; Danae M Sharp; Akanksha Arvind; Patric J Jansson; Des R Richardson
Journal:  J Biol Chem       Date:  2013-09-23       Impact factor: 5.157

10.  P-Glycoprotein is not present in mitochondrial membranes.

Authors:  Jill K Paterson; Michael M Gottesman
Journal:  Exp Cell Res       Date:  2007-04-24       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.